The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced b…

Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer

~Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06997029

Phase 2

Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.

The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compare…

Advanced Ovarian Cancer

~Estimated

~$10 – $8,750

Allarity TherapeuticsNCT03878849

Phase 2

A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)

The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly…

Advanced Ovarian Cancer

~Estimated

~$10 – $8,750

Aston Sci. Inc.NCT05794659